文献速递垂体与肾上腺疾病

家族性孤立性和早发性垂体瘤中AIP基因检测与临床筛查的显著获益

Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

这项为期12年的前瞻性观察研究纳入1477例家族性孤立性垂体腺瘤先证者及家属和早发或大腺瘤散发患者,比较前瞻性诊断与临床就诊的AIP突变阳性垂体神经内分泌肿瘤患者,发现前瞻性诊断者病灶更小、侵袭更少、治疗更少、结局更好,提示遗传与临床筛查的获益。

要点

  • 前瞻性诊断的AIP突变阳性垂体瘤患者较临床就诊者病灶更小、鞍上扩展或海绵窦侵袭更少。
  • 前瞻性诊断者所需治疗更少、手术更少且无放疗,末次随访时活动性疾病和垂体功能减退更少。
  • AIP突变患者较AIP阴性者更多为男性、更年轻,更多伴GH过多、垂体卒中及鞍上扩展。

核心结论

  • 前瞻性诊断的AIP突变阳性患者结局优于临床就诊者,证明遗传和临床筛查的获益。
  • AIP相关垂体疾病谱广泛,从侵袭性生长的病变到稳定或惰性病程均可出现。

研究设计与样本

  • 12年前瞻性观察性研究,纳入家族性孤立性垂体腺瘤家系先证者及家属和发病年龄≤18岁或≤30岁大腺瘤的散发患者,共1477例。
  • 在垂体疾病转诊中心开展的合作研究,比较前瞻性诊断(n=22)与临床就诊(n=145)的AIP突变阳性垂体神经内分泌肿瘤患者,以及AIP突变阳性(n=167)与AIP阴性(n=1310)患者。

主要发现

  • 前瞻性诊断的AIP突变阳性患者较临床就诊者病灶更小,鞍上扩展或海绵窦侵袭更少,所需治疗更少、手术更少且无放疗。
  • 前瞻性诊断者末次随访时活动性疾病和垂体功能减退的病例更少。
  • AIP突变阳性患者较AIP阴性者更多为男性、更年轻,更多伴GH过多、垂体卒中、鞍上扩展,更多患者需要多模式治疗包括放疗。
  • 伴GH过多的AIP突变阳性患者(n=136)身高高于AIP阴性者(n=650)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene are responsible for a subset of familial isolated pituitary adenoma (FIPA) cases and sporadic pituitary neuroendocrine tumors (PitNETs). OBJECTIVE: To compare prospectively diagnosed AIP mutation-positive (AIPmut) PitNET patients with clinically presenting patients and to compare the clinical characteristics of AIPmut and AIPneg PitNET patients. DESIGN: 12-year prospective, observational study. PARTICIPANTS & SETTING: We studied probands and family members of FIPA kindreds and sporadic patients with disease onset ≤18 years or macroadenomas with onset ≤30 years (n = 1477). This was a collaborative study conducted at referral centers for pituitary diseases. INTERVENTIONS & OUTCOME: AIP testing and clinical screening for pituitary disease. Comparison of characteristics of prospectively diagnosed (n = 22) vs clinically presenting AIPmut PitNET patients (n = 145), and AIPmut (n = 167) vs AIPneg PitNET patients (n = 1310). RESULTS: Prospectively diagnosed AIPmut PitNET patients had smaller lesions with less suprasellar extension or cavernous sinus invasion and required fewer treatments with fewer operations and no radiotherapy compared with clinically presenting cases; there were fewer cases with active disease and hypopituitarism at last follow-up. When comparing AIPmut and AIPneg cases, AIPmut patients were more often males, younger, more often had GH excess, pituitary apoplexy, suprasellar extension, and more patients required multimodal therapy, including radiotherapy. AIPmut patients (n = 136) with GH excess were taller than AIPneg counterparts (n = 650). CONCLUSIONS: Prospectively diagnosed AIPmut patients show better outcomes than clinically presenting cases, demonstrating the benefits of genetic and clinical screening. AIP-related pituitary disease has a wide spectrum ranging from aggressively growing lesions to stable or indolent disease course.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Marques P, Caimari F, Hernández-Ramírez LC, et al. Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. J Clin Endocrinol Metab. 2020. PMID: 31996917. doi:10.1210/clinem/dgaa040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。